Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Proof of Mechanism Study to Explore the Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis

NCT04478825 is registered in ClinicalTrials.gov with Bridge Biotherapeutics, Inc. as lead sponsor.

NCT NCT04478825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04478825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Proof of Mechanism Study to Explore the Efficacy and Safety of Rectally Administered BBT-401-1S in Subjects With Ulcerative Colitis
Lead sponsor
Bridge Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
June 1, 2021
Completion date
August 24, 2021
Enrollment
2 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis